Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017139623) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/139623 International Application No.: PCT/US2017/017435
Publication Date: 17.08.2017 International Filing Date: 10.02.2017
IPC:
A61K 45/06 (2006.01) ,C07K 16/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
IMMUNOMEDICS, INC. [US/US]; 300 American Road Morris Plains, New Jersey 07950, US
Inventors:
CHANG, Chien-Hsing; US
GOLDENBERG, David M.; US
Agent:
NAKASHIMA, Richard, A.; US
Priority Data:
62/293,53010.02.2016US
62/329,78829.04.2016US
62/336,98516.05.2016US
Title (EN) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
(FR) LA COMBINAISON INHIBITEURS ABCG2-SACITUZUMAB GOVITÉCAN (IMMU-132) SURMONTE LA RÉSISTANCE À SN-38 DANS LES CANCERS EXPRIMANT TROP-2
Abstract:
(EN) The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
(FR) L'invention concerne des conjugués anticorps-médicament (ADC) thérapeutiques comprenant un médicament lié à un anticorps dirigé contre le cancer ou à un fragment de celui-ci se liant à l'antigène. De préférence, le médicament est SN-38. Plus préférablement, l'anticorps ou fragment de celui-ci se lie à Trop-2 et la thérapie est utilisée pour traiter un cancer positif à Trop-2. Idéalement, l'anticorps est hRS7. L'ADC, en combinaison avec un inhibiteur d'ABCG2, est administré à un sujet atteint d'un cancer. La polythérapie décrite est efficace pour traiter les cancers qui sont résistants au médicament seul et/ou à l'ADC seul.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3011372CN108601841IN201817027046EP3413914